Metelimumab

DB18695Experimental

Metelimumab (CAT-192) is a monoclonal antibody targeted against transforming growth factor (TGF) beta-1.

Mechanism: Pharmacologically active on Transforming growth factor beta-1 proprotein
Curator reviewed
Code names: CAT-192

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Metelimumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.